

# Umar Mahmood

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9590563/publications.pdf>

Version: 2024-02-01

94  
papers

8,324  
citations

136950  
32  
h-index

46799  
89  
g-index

96  
all docs

96  
docs citations

96  
times ranked

12802  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology, 2022, , 1.	2.6	4
2	Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. Pharmaceutics, 2022, 14, 1460.	4.5	2
3	Improving staging of rectal cancer in the pelvis: the role of PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1235-1245.	6.4	40
4	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	6.4	6
5	RSNA International Trends: A Global Perspective on the COVID-19 Pandemic and Radiology in Late 2020. Radiology, 2021, 299, E193-E203.	7.3	23
6	Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2021, 44, 1439-1447.	2.0	2
7	HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. Molecular Imaging and Biology, 2021, 23, 930-940.	2.6	2
8	Abstract 1309: HSV1 oncolytic therapy for breast cancer meningeal metastases. , 2021, , .		0
9	Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research, 2021, 27, 5353-5364.	7.0	13
10	Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases. Investigative Radiology, 2021, 56, 621-628.	6.2	15
11	PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1976-1986.	6.4	25
12	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1871-1884.	6.4	32
13	HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance. Frontiers in Oncology, 2020, 10, 554704.	2.8	6
14	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. Oncologist, 2020, 25, 652-660.	3.7	11
15	Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response. , 2020, 8, e000291.		32
16	A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases.. Journal of Clinical Oncology, 2020, 38, 1062-1062.	1.6	0
17	Clinical impact of PET/MR in treated colorectal cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2260-2269.	6.4	28
18	Neuroepigenetic signatures of age and sex in the living human brain. Nature Communications, 2019, 10, 2945.	12.8	36

#	ARTICLE	IF	CITATIONS
19	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 631-640.	7.1	198
20	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205.	7.0	85
21	The Impact of Positron Emission Tomography with <sup>18</sup> F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.4	113
22	Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 230-242.	1.0	5
23	Radiotheranostics in Cancer Diagnosis and Management. Radiology, 2018, 286, 388-400.	7.3	91
24	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. Journal of Oncology Practice, 2018, 14, e722-e728.	2.5	31
25	C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1024-1028.	0.8	18
26	Specific <sup>18</sup> F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone- $\alpha$ -Binding Globulin. Journal of Nuclear Medicine, 2018, 59, 1538-1543.	5.0	5
27	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics, 2018, 8, 3380-3391.	10.0	11
28	Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2147-2154.	6.4	28
29	The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points. Urology, 2018, 119, 23-31.	1.0	6
30	Lower Gastrointestinal Tract Applications of PET/Computed Tomography and PET/MR Imaging. Radiologic Clinics of North America, 2018, 56, 821-834.	1.8	7
31	Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide. Molecular Imaging and Biology, 2018, 20, 300-308.	2.6	18
32	Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 62-69.	1.0	12
33	PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. British Journal of Cancer, 2017, 116, 893-902.	6.4	52
34	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Research, 2017, 77, 2318-2327.	0.9	235
35	Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdominal Radiology, 2017, 42, 1141-1151.	2.1	52
36	<sup>18</sup> F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	7.0	66

#	ARTICLE	IF	CITATIONS
37	Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. International Journal of Oncology, 2017, 51, 281-288.	3.3	52
38	An overview of PET/MR, focused on clinical applications. Abdominal Radiology, 2017, 42, 631-644.	2.1	21
39	A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of Ga-DOTATOC in healthy volunteers. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 53-62.	1.0	2
40	Pilot Clinical Trial of Indocyanine Green Fluorescence-Augmented Colonoscopy in High Risk Patients. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	4
41	Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics, 2016, 6, 2028-2038.	10.0	15
42	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	5.0	28
43	Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles. Journal of Nuclear Medicine, 2016, 57, 105S-110S.	5.0	8
44	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. Journal of Nuclear Medicine, 2016, 57, 1607-1611.	5.0	105
45	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2016, 15, 234-242.	1.9	17
46	Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 176-84.	1.0	6
47	Fluorescence multi-scale endoscopy and its applications in the study and diagnosis of gastro-intestinal diseases: set-up design and software implementation. Proceedings of SPIE, 2015, , .	0.8	0
48	Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degradar. Clinical Cancer Research, 2015, 21, 1340-1347.	7.0	32
49	Prospective Trial with Optical Molecular Imaging for Percutaneous Interventions in Focal Hepatic Lesions. Radiology, 2015, 274, 917-926.	7.3	23
50	Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer. Journal of Nuclear Medicine, 2015, 56, 1246-1251.	5.0	17
51	PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 379-89.	1.0	10
52	Fluorescent Nanoparticle Imaging Allows Noninvasive Evaluation of Immune Cell Modulation in Esophageal Dysplasia. Molecular Imaging, 2014, 13, 7290.2014.00003.	1.4	12
53	An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis. Theranostics, 2014, 4, 893-903.	10.0	29
54	Interventional Optical Molecular Imaging Guidance during Percutaneous Biopsy. Radiology, 2014, 271, 770-777.	7.3	22

#	ARTICLE	IF	CITATIONS
55	A novel direct activator of <scp>AMPK</scp> inhibits prostate cancer growth by blocking lipogenesis. EMBO Molecular Medicine, 2014, 6, 519-538.	6.9	168
56	Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11419-11424.	7.1	40
57	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. Cancer Research, 2014, 74, 4111-4121.	0.9	11
58	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	16.8	1,892
59	A container closure system that allows for greater recovery of radiolabeled peptide compared to the standard borosilicate glass system. Applied Radiation and Isotopes, 2013, 80, 99-102.	1.5	5
60	Optical Imaging of Periostin Enables Early Endoscopic Detection and Characterization of Esophageal Cancer in Mice. Gastroenterology, 2013, 144, 294-297.	1.3	28
61	Free Somatostatin Receptor Fraction Predicts the Antiproliferative Effect of Octreotide in a Neuroendocrine Tumor Model: Implications for Dose Optimization. Cancer Research, 2013, 73, 6865-6873.	0.9	19
62	Metforminâ€”an Adjunct Antineoplastic Therapyâ€”Divergently Modulates Tumor Metabolism and Proliferation, Interfering with Early Response Prediction by <sup>18</sup>F-FDG PET Imaging. Journal of Nuclear Medicine, 2013, 54, 252-258.	5.0	23
63	Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors. Stem Cells, 2013, 31, 1706-1714.	3.2	89
64	Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 272-81.	1.0	49
65	Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy. Theranostics, 2012, 2, 227-234.	10.0	43
66	Science to Practice: Can a Targeted Nanoparticle Be Used to Image Autoimmune Nephritis?. Radiology, 2010, 255, 309-310.	7.3	1
67	In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis, 2010, 212, 181-187.	0.8	51
68	Quantitative Endovascular Fluorescence-based Molecular Imaging through Blood of Arterial Wall Inflammation. Radiology, 2009, 251, 813-821.	7.3	17
69	Science to Practice: Can an Enzyme-sensitive MR Contrast Agent Be Used to Image Inflammation in Aneurysms?. Radiology, 2009, 252, 627-628.	7.3	5
70	Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. Gynecologic Oncology, 2009, 112, 616-622.	1.4	74
71	Abrogation of antibodyâ€”induced arthritis in mice by a selfâ€”activating viridin prodrug and association with impaired neutrophil and endothelial cell function. Arthritis and Rheumatism, 2009, 60, 2314-2324.	6.7	10
72	Quantitative Real-time Catheter-based Fluorescence Molecular Imaging in Mice. Radiology, 2007, 245, 523-531.	7.3	43

#	ARTICLE	IF	CITATIONS
73	Inflammatory arthritis can be reined in by CpG-induced DCâ€“NK cell cross talk. Journal of Experimental Medicine, 2007, 204, 1911-1922.	8.5	84
74	Current and Future Imaging Paradigms in Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2007, 18, 132-138.	0.3	2
75	Molecular Imaging in Gastrointestinal Disease. Gastroenterology, 2007, 132, 11-14.	1.3	18
76	Real-Time Multichannel Imaging Framework for Endoscopy, Catheters, and Fixed Geometry Intraoperative Systems. Molecular Imaging, 2007, 6, 7290.2007.00012.	1.4	17
77	Real-time multichannel imaging framework for endoscopy, catheters, and fixed geometry intraoperative systems. Molecular Imaging, 2007, 6, 147-55.	1.4	14
78	Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5947-5952.	7.1	537
79	Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nature Immunology, 2006, 7, 284-292.	14.5	171
80	Near infrared thoracoscopy of tumoral protease activity for improved detection of peripheral lung cancer. International Journal of Cancer, 2006, 118, 2672-2677.	5.1	57
81	Can a Clinically Used Chemoembolization Vehicle Improve Transgene Delivery?. Radiology, 2006, 240, 619-620.	7.3	1
82	Molecular MR Imaging Probes. Proceedings of the IEEE, 2005, 93, 800-808.	21.3	7
83	Methotrexate-Induced Accumulation of Fluorescent Annexin V in Collagen-Induced Arthritis. Molecular Imaging, 2005, 4, 153535002005041.	1.4	22
84	Can MR Imaging Be Used to Track Delivery of Intravascularly Administered Stem Cells?. Radiology, 2004, 233, 625-626.	7.3	9
85	Catheter-based in Vivo Imaging of Enzyme Activity and Gene Expression: Feasibility Study in Mice. Radiology, 2004, 231, 659-666.	7.3	62
86	Miniaturized Multichannel Near Infrared Endoscope for Mouse Imaging. Molecular Imaging, 2003, 2, 153535002003031.	1.4	6
87	Pan and Sentinel Lymph Node Visualization Using a Near-Infrared Fluorescent Probe. Molecular Imaging, 2003, 2, 153535002003021.	1.4	6
88	Miniaturized Multichannel Near Infrared Endoscope for Mouse Imaging. Molecular Imaging, 2003, 2, 350-357.	1.4	71
89	Near-infrared optical imaging of proteases in cancer. Molecular Cancer Therapeutics, 2003, 2, 489-96.	4.1	207
90	Feasibility of in Vivo Multichannel Optical Imaging of Gene Expression: Experimental Study in Mice. Radiology, 2002, 224, 446-451.	7.3	328

#	ARTICLE	IF	CITATIONS
91	Arthritis Critically Dependent on Innate Immune System Players. Immunity, 2002, 16, 157-168.	14.3	631
92	Coded Aperture Nuclear Scintigraphy: A Novel Small Animal Imaging Technique. Molecular Imaging, 2002, 1, 153535002002213.	1.4	3
93	In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology, 1999, 17, 375-378.	17.5	1,578
94	Preparation of a Cathepsin D Sensitive Near-Infrared Fluorescence Probe for Imaging. Bioconjugate Chemistry, 1999, 10, 892-896.	3.6	212